Lacticaseibacillus rhamnosus Strains for Alleviation of Irritable Bowel Disease and Chronic Fatigue Syndrome.
Zhang, Liang, Ni, Xue, Jiang, Minzhi et al. · Microorganisms · 2024 · DOI
Quick Summary
Researchers studied special strains of a probiotic bacteria called Lacticaseibacillus rhamnosus to see if they could help with ME/CFS and irritable bowel syndrome (IBS). After testing 21 different strains, they found that two strains (WL11 and WL17) reduced fatigue-related symptoms like weight loss, anxiety, and memory problems in mice with CFS-like illness, and also eased IBS symptoms like gut sensitivity and inflammation. However, these results are from animal studies, so we don't yet know if the same effects will work in people.
Why It Matters
ME/CFS lacks approved pharmacological treatments, and emerging evidence links gut dysbiosis to symptom severity. This study provides mechanistic data suggesting specific probiotic strains may modulate immune and neurological dysfunction in CFS, offering a potential avenue for microbiota-targeted therapy that warrants human investigation.
Observed Findings
Strains WL11 and WL17 reduced slow body weight gain in CFS mouse models
Both strains decreased anxiety-like behavior and improved memory and cognitive function in CFS-affected mice
WL11 and WL17 reduced pro-inflammatory cytokines (TNF-α and IL-6) in IBS mouse models
These strains alleviated visceral hypersensitivity and intestinal dysmotility in IBS models
Inferred Conclusions
Lacticaseibacillus rhamnosus strains WL11 and WL17 have probiotic potential for alleviating CFS-related symptoms through immune modulation and cognitive improvement
These strains may benefit IBS patients by reducing inflammation and gut hypersensitivity
Strain-specific effects suggest that not all L. rhamnosus strains are equally therapeutic, necessitating careful strain selection for clinical use
Remaining Questions
Will WL11 and WL17 demonstrate similar efficacy and safety in human ME/CFS and IBS patients?
What are the specific mechanistic pathways by which these strains modulate immune function and neurological symptoms in humans?
How do these strains perform in comparison with other established probiotics or standard-of-care treatments?
What This Study Does Not Prove
This study does not demonstrate that these probiotic strains are effective in humans with ME/CFS or IBS—only in mouse models. It does not prove causation between the tested strains and symptom alleviation; the mechanisms identified may not translate to human physiology. It does not establish safety, optimal dosing, or long-term efficacy in any human population.